South Korea Prescription drugs: key facts
Key players
Who makes the heart and cholesterol generics sold in Korea after patent expiry?
Most sellers do not own a factory; contract manufacturers make the product, and the winner is whoever carries it into clinics, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Channels and distribution
Which customers do Korean makers of heart and cholesterol generics target first?
Clinics: domestic makers run clinic-heavy sales forces, with several clinic reps for every hospital rep, as their main weapon against the originator, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Do clinical trials at top university hospitals help a heart drug win hospital listings in Korea?
Yes: trial sites are the natural first hospital to list the drug, though top hospitals run several competing trials, which raises trial costs, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Is national reimbursement listing enough to sell a heart drug to Korean hospitals?
No: each hospital's drug committee is a separate gate where price matters, so firms without strong hospital coverage usually find a partner, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Pricing
Do Korean drug-pricing officials examine expensive generic price filings more closely?
Officials rely largely on submitted documents: moderately priced filings pass easily, while expensive ones are examined hard, so most makers price modestly at listing, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Regulation
How have promotion rules changed the way Korean heart-drug makers sell to doctors?
After official warnings over illegal support, firms cut sponsorship and rely on clinical data, symposia and bundles with their other cardiovascular drugs, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Does winning a patent challenge give a generic heart drug a launch date in Korea?
Practitioners say a court win is a queue ticket, not a launch date; Entresto challengers won, yet approvals stand at 0 (Dailypharm, 20 Jan 2026), as cited in KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Market entry
What should a Japanese or Chinese maker do to enter Korea's heart-drug generic market?
Enter early with a partner that has a clinic sales force, or bring what the crowd cannot copy fast: a combination, new strength or clinical data, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
How the trade works
In Korea, does the first generic heart or cholesterol drug to launch win most of the share?
Yes, practitioners expect the first entrant to win most share; later entrants watch its launch numbers before setting price, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
How quickly do clinic doctors switch patients to a newly listed heart drug in Korea?
Doctors switch patients in the first month after listing, and stable heart-pill patients do not usually switch twice, so early listings often keep prescriptions, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
How do original heart-drug brands defend their share against generic entrants in Korea?
They bring outcome data, new strengths or indications and cut price selectively where it hurts most, giving doctors a reason to stay, per KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia).
Source: KIRA field research (modelled interview), 2026 · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
Who decides
Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.
Who specifies
- Each hospital has its own drug committee, a separate listing gate after national reimbursement, and price matters there as well. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia)
Who buys and pays
- Most blood-pressure and cholesterol patients get their monthly prescription at a neighbourhood clinic, so the clinic doctor is the buyer a new product must win. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia)
- Contract sales organizations carry much of the outsourced sales effort, and high commissions prompt questions about what they are paid to do. marketing managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia)
Who carries the risk
No field statement yet
How the trade works
Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.
- A partner's sales team can switch sides, so an originator that picks a local partner is also picking whose clinic reps carry its brand. marketing managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Late entrants wait for the first launch's results, then set their own price and story, so the first listing shapes what follows. marketing managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Originators defend themselves with clinical outcome data, new strengths or indications and selective price cuts where the pressure is greatest. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Clinic doctors switch their patients in the first month after a new listing, and stable heart-pill patients do not usually switch twice. sales managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Most blood-pressure and cholesterol patients get their monthly prescription at a neighbourhood clinic, so the clinic doctor is the buyer a new product must win. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- A plan built only on being first, without a product doctors want to stay on, can end up very busy and not very profitable. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Entrants pair a drug with their other cardiovascular products in one package, so the sales rep has several reasons to visit a clinic. sales managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Contract sales organizations carry much of the outsourced sales effort, and high commissions prompt questions about what they are paid to do. marketing managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- After official warnings over illegal support, firms cut sponsorship and lean on clinical data, symposia and joint packages instead. marketing managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Each hospital has its own drug committee, a separate listing gate after national reimbursement, and price matters there as well. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Pricing officials rely largely on the documents companies submit, so moderately priced filings go through easily while expensive ones are examined hard. drug-pricing officials · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Top hospitals run several competing trials at once, which raises trial costs for companies that place studies there. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Firms without strong hospital coverage usually find a partner to cover the larger hospitals rather than building a team from zero. marketing managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- Domestic makers rely on clinic-heavy sales forces, with several clinic reps for every hospital rep, as their main weapon against the originator. sales managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor
- A stepped price cut that now reaches later entrants sooner may stop the tail of late entrants from coming, which matters more to a company than the base rate. product managers at domestic drug makers · KIRA field research (interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials across Asia) · How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor